DEFA14A: Artiva Biotherapeutics to Hold Annual Stockholders Meeting on June 24, 2025

Artiva Biotherapeutics will hold its annual stockholders meeting on June 24, 2025, to vote on director election, auditor ratification, and an equity incentive plan amendment.

Summary

• Artiva Biotherapeutics will hold its annual meeting of stockholders on June 24, 2025.
• Stockholders of record as of April 25, 2025, are eligible to vote.
• The meeting will be held online.
• The proposals include electing Daniel Baker, Ph.D. as Class I director, ratifying the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approving an amendment to the 2024 Equity Incentive Plan to increase the number of shares by 1,214,580.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating normal corporate governance activities. The sentiment is neutral to slightly positive as it reflects the company's adherence to regulatory requirements and engagement with shareholders.

Positives

• The company is holding its annual meeting, allowing stockholders to participate in key decisions.
• Stockholders have the option to attend the meeting online, increasing accessibility.
• The proposals are clearly outlined, allowing stockholders to make informed decisions.

Future Outlook

The document outlines the agenda for the upcoming annual meeting, focusing on governance and equity incentives.

Industry Context

This is a standard proxy statement related to an annual meeting, which is a routine part of corporate governance for publicly traded companies.

Stakeholder Impact

• Stockholders have the opportunity to vote on key company matters.
• The outcome of the votes will impact the company's governance and equity structure.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the annual meeting on June 24, 2025.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Artiva Biotherapeutics, Director Election, Auditor Ratification, Equity Incentive Plan, KPMG, Daniel Baker